Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7
Primary Industries
- Drugs
- Diagnostic
- Pharmaceuticals
- Therapeutic
- cardiac
- Disease
- Imaging
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 27250
License Grant
The Company granted an exclusive license to manufacture and market Adenocard in the United States and Canada. Adenocard(R) – a sterile formulation of adenosine for injection indicated for the treatment of abnormally rapid heartbeats originating in the upper chambers of the heart, so-called paroxysmal supraventricular tachycardia.
License Property
Adenoscan is a sterile formulation of adenosine (3mg/ml) available in 30ml or 20ml vials for infusion indicated as an adjunct to thallium cardiac imaging in the evaluation of coronary artery disease. Adenoscan is used by doctors to help diagnose heart disease. The drug is used by doctors to simulate stress for elderly patients and others who cannot exercise on a treadmill. In October 1988, the Company completed clinical trial and received FDA approval to market Adenocard in the United States.
Field of Use
The rights granted apply to the medical industry.
IPSCIO Record ID: 27373
License Grant
The Licensor granted the French Licensee the rights to exclusively manufacture and market ADENOCARD in Europe and countries other than the United States and Canada.
License Property
ADENOCARD is a sterile formulation of adenosine (3mg/ml) available in 2ml vials and 2-4ml pre filled syringes for intravenous injection to restore normal heart rhythm in patients with abnormally rapid heartbeats originating in the upper chambers of the heart, so-called paroxysmal supra ventricular tachycardia.
In October 1988, the Company completed clinical trial and received FDA approval to market ADENOCARD in the United States. In September 1991, the Licensee received marketing approval under the trade name ADENOCOR in the United Kingdom and in May 1992, received marketing approval under the trade name KRENOSIN in Switzerland.
IPSCIO Record ID: 26514
License Grant
The Company granted a French pharmaceutical company the exclusive rights to manufacture and market Adenoscan worldwide except in the United States, Canada, Japan, Korea and Taiwan. In June 1995, the Licensee received marketing approval for Adenoscan in the United Kingdom and in February 1997.
License Property
Adenoscan® – a sterile formulation of adenosine for infusion – indicated as an adjunct to thallium cardiac imaging for the evaluation of coronary artery disease in patients unable to exercise adequately, so-called pharmacological stress. Commercially available from Fujisawa in the United States and Canada since 1995. In May 1995, the Company complete clinical trial and received from the FDA marketing clearance for Adenoscan in the United States.
Field of Use
The rights granted apply to the healthcare industry.
IPSCIO Record ID: 27372
License Grant
The University granted to the Company an exclusive license to exploit in the United States and Canada the use of Adenosine for the treatment of supraventricular tachycardia that is caused by re-entry in the A-V node or an accessory pathway of the human heart.
License Property
Adenocard (R) – a sterile formulation of adenosine for injection indicated for the treatment of abnormally rapid heartbeats originating in the upper chambers of the heart, so-called paroxysmal supraventricular tachycardia.
Field of Use
Licensee is a pharmaceutical company dedicated to being a leader in the global commercialization of cardiovascular medicines and adenosine-based products leading to superior growth in shareholder value.
IPSCIO Record ID: 26861
License Grant
The Company granted a pharmaceutical company an exclusive license in the United States and Canada to manufacture and market Adenoscan. Adenoscan® – a sterile formulation of adenosine for infusion – indicated as an adjunct to thallium cardiac imaging for the evaluation of coronary artery disease in patients unable to exercise adequately, so-called pharmacological stress. Commercially available from the Japanese pharmaceutical company in the United States and Canada since 1995, the drug also is sold by Sanofi in the United Kingdom and pending registration and approval in other countries of the world. The Company completed clinical trial and received from the FDA marketing clearance for Adenoscan in the United States. In May 1995, the Company complete clinical trail and received from the FDA marketing clearance for Adenoscan in the United States.
IPSCIO Record ID: 26859
License Grant
The Company obtained from a Canadian manufacturer of radiopharmaceuticals, the right to develop and market Viascint in the United States. Upon FDA approval, the Company may sublicense the marketing rights for Viascint.
License Property
Viascint – a sterile radiopharmaceutical formulation of iodine123-iodophenylpentadecanoic acid for injection – subject to FDA approval, as to which no assurance can be given, proposed to be used to determine the presence of hibernating, or reversibly injured heart muscle and thereby predict which patients are most likely to experience improvement in cardiac function following, and thus benefit from, coronary artery bypass graft (CABG) surgery, and to assist physicians in the selection of patients for such surgery.
The Company completed Phase III clinical testing, and the results indicated that the product provides the means to predict, with high accuracy, which patients will have improvement in cardiac functioning following revascularization. The Company filed an NDA in 1996.
Field of Use
The rights granted apply to the heart muscle.
IPSCIO Record ID: 369377
License Grant
The University grants an exclusive, worldwide license in the Field under the Licensed Know-how and the Licensed Patents to make, have made, use, import, offer for sale, develop, have developed, promote, have promoted and sell Licensed Products throughout term hereof.
License Property
Licensor owns certain proprietary know-how, patent applications and patents pertaining to human therapeutic uses of adenosine and adenosine derivatives, receptor-selective adenosine derivatives, and compounds that interact with adenosine receptors or their signaling pathways.
Patents relate to Method For Improving Insulin Sensitivity Using An Adenosine Receptor Antagonist, and, Methods And Compositions For Treating Inflammatory Response.
Field of Use
The Agreement includes certain intellectual property relating to the Licensee’s late-stage drug candidate, apadenoson, trademarked Stedivaze, a selective adenosine receptor 2A agonist and potential best-in-class coronary vasodilator for use in nuclear-SPECT myocardial perfusion imaging, which currently is in Phase III of clinical development.
Stedivaze is a potential best-in-class vasodilator for use in cardiac stress testing. The study will evaluate the safety and efficacy of Stedivaze (apadenoson) for use as a pharmacologic stress agent in myocardial perfusion imaging (MPI), a method for detecting defects in the blood supply to the heart. The Phase III trial will also compare the tolerability of Stedivaze to adenosine, a standard pharmacologic stress agent used in MPI scans.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
